drugset
drugset / Trial / NCT01306305

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere

NCT01306305 ↗

Phase 4 Completed 110 enrolled Crucell Holland BV
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to assess whether the Northern Hemisphere 2010/2011 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines

Timeline

Start
2010-06
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Inflexal V Vaccine 0.5 ml Intramuscular

Indications

influenza